AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.
In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.
A 36-year-old woman presents with history of previous breast implants and induration of the left breast. What is your diagnosis?
In this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program.
A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence.
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in breast cancer, and the importance of understanding how resistance to these agents develops.
A 38-year-old woman with a history of tobacco use presents with shortness of breath, cough, chest pain, and general malaise. What is your diagnosis?
Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.
In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.
In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial.
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.